← Back to Search

Cancer Vaccine

NM32-2668 for Melanoma

Phase 1

Recruiting

Research Sponsored by Numab Therapeutics AG

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment)

Awards & highlights

Study Summary

This trial is testing a new drug called NM32-2668 in adult patients with advanced solid tumors. The main goals are to check the safety and effectiveness of the drug, find the highest safe dose

Who is the study for?

Adults with certain advanced solid tumors, including various cancers like endometrial, melanoma, ovarian, kidney, breast cancer and more. Participants must meet specific health criteria to join.Check my eligibility

What is being tested?

NM32-2668 is being tested for safety and effectiveness in treating selected advanced solid tumors. This early-phase trial will determine the best dose and gather initial data on how well it works.See study design

What are the potential side effects?

Since this is a first-in-human study of NM32-2668, potential side effects are not yet fully known but may include typical drug reactions such as nausea, fatigue, or allergic responses.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Duration of dose interruptions/reductions

Frequency of dose interruptions/reductions

Incidence of Dose Limiting Toxicities (DLTs)

+1 more

Secondary outcome measures

Assessment of accumulation ratios of AUC (ARauc) of NM32-2668 in serum

Assessment of accumulation ratios of Cmax (ARcmax) of NM32-2668 in serum

Assessment of accumulation ratios of Cmin (ARcmin) of NM32-2668 in serum

+19 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: NM32-2668Experimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Numab Therapeutics AGLead Sponsor

2 Previous Clinical Trials

192 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has NM32-2668 received approval from the FDA?

"As a Phase 1 trial, the safety rating for NM32-2668 from our team at Power is designated as 1 due to the scarcity of corroborating data regarding its safety and effectiveness."

Answered by AI

Is this medical study currently open for enrollment?

"As per clinicaltrials.gov, this investigation is currently in the process of recruiting suitable participants. The original posting date for this research was 29th March 2024, with the most recent update made on 1st March 2024."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

2024. "NM32-2668 in Adult Patients With Selected Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06299163.

All > Lung Adenocarcinoma > Liposarcoma